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Chronic effects of cannabis on sensory gating
Abstract
Chronic cannabis use has been associated with neurocognitive deficits, alterations in brain structure and
function, and with psychosis. This study investigated the effects of chronic cannabis use on P50 sensory-gating
in regular users, and explored the association between sensory gating, cannabis use history and the
development of psychotic-like symptoms. Twenty controls and 21 regular cannabis users completed a P50
paired-click (S1 and S2) paradigm with an inter-pair interval of 9. s. The groups were compared on P50
amplitude to S1 and S2, P50 ratio (S2/S1) and P50 difference score (S1-S2). While cannabis users overall did
not differ from controls on P50 measures, prolonged duration of regular use was associated with greater
impairment in sensory gating as indexed by both P50 ratio and difference scores (including after controlling
for tobacco use). Long-term cannabis users were found to have worse sensory gating ratios and difference
scores compared to short-term users and controls. P50 metrics did not correlate significantly with any
measure of psychotic-like symptoms in cannabis users. These results suggest that prolonged exposure to
cannabis results in impaired P50 sensory-gating in long-term cannabis users. While it is possible that these
deficits may have pre-dated cannabis use and reflect a vulnerability to cannabis use, their association with
increasing years of cannabis use suggests that this is not the case. Impaired P50 sensory-gating ratios have also
been reported in patients with schizophrenia and may indicate a similar underlying pathology.
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Chronic cannabis use has been associated with neurocognitive deficits, alterations in brain structure 
and function, and with psychosis. This study investigated the effects of chronic cannabis use on P50 sensory-
gating in regular users, and explored the association between sensory gating, cannabis use history and the 
development of psychotic-like symptoms. Twenty controls and 21 regular cannabis users completed a P50 
paired-click (S1 and S2) paradigm with an inter-pair interval of 9 seconds.  The groups were compared on 
P50 amplitude to S1 and S2, P50 ratio (S2/S1) and P50 difference score (S1-S2). While cannabis users 
overall did not differ from controls on P50 measures, prolonged duration of regular use was associated with 
greater impairment in sensory gating as indexed by both P50 ratio and difference scores (including after 
controlling for tobacco use). Long-term cannabis users were found to have worse sensory gating ratios and 
difference scores compared to short-term users and controls. P50 metrics did not correlate significantly with 
any measure of psychotic-like symptoms in cannabis users. These results suggest that prolonged exposure to 
cannabis results in impaired P50 sensory-gating in long-term cannabis users. While it is possible that these 
deficits may have pre-dated cannabis use and reflect a vulnerability to cannabis use, their association with 
increasing years of cannabis use suggests that this is not the case.  Impaired P50 sensory-gating ratios have 
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1.0 Introduction 
Cannabis sativa is the most commonly used illicit substance in the world. Regular and prolonged 
exposure to cannabis is associated with impaired cognition, particularly deficits in attention, learning and 
memory (Solowij and Michie, 2007; Solowij and Pesa, 2010), alterations in brain structure and function 
(Solowij et al., 2011; Yücel et al., 2008a; Yücel et al., 2008b), and deficits in electrophysiological indices of 
pre-attentive processes (e.g. P50: Edwards et al., 2009; Patrick et al., 1999; Patrick and Struve, 2002; Patrick 
and Struve, 2000; Rentzsch et al., 2007; and mismatch negativity, MMN: Greenwood et al., in revision; 
Rentzsch et al., 2011; Roser et al., 2010) as well as selective attention (e.g. processing negativity and P300: 
Solowij et al., 1995). Chronic cannabis use has also been shown to increase the risk of developing psychotic 
symptoms in a dose-response fashion (Semple et al., 2005), and is considered by some to be a component 
cause of schizophrenia in vulnerable individuals (D'Souza et al., 2009; Murray et al., 2007). Δ
9
-
Tetrahydrocannabinol (THC) is the primary psychoactive constituent of cannabis and is linked with altered 
cognition and the induction of psychotic-like symptoms (D'Souza et al., 2009). The subjective, behavioural and 
cognitive effects produced by THC are most likely due to the action of THC as a partial agonist at central 
cannabinoid (e.g. CB1) receptor sites (Pertwee, 2008), altering the regulatory action of the endocannabinoid 
system on synaptic transmission and other neurotransmitter signalling, such as gamma-aminobutyric acid 
(GABA), glutamate and dopamine (Lopez-Moreno et al., 2008; Mathur and Lovinger, 2012). CB1 receptors 
occur in high density throughout the brain, particularly in the hippocampus, anterior cingulate, basal ganglia 
and the cerebellum; regions which are involved in cognition and are particularly important for attention, 
learning and memory (Bhattacharyya et al., 2009; Bossong and Niesink, 2010; Iversen, 2004). Impaired 
cognition in chronic cannabis users is thought to be underpinned at least in part, by alterations to the 
regulatory role of the endocannabinoid system on synaptic plasticity following prolonged and regular exposure 
to exogenous cannabinoids such as THC (Hampson et al., 2011; Heifets and Castillo, 2009; Hoffman et al., 
2007; Puighermanal et al., 2012). In light of deficits in cognition (e.g., selective attention, verbal learning and 
inhibition, Solowij and Michie, 2007), and alterations in brain function (e.g., prefrontal cortical, cingular, 
hippocampal and cerebellar activation in imaging studies, Solowij and Michie, 2007; Martin-Santos et al., 
2010) and structure (e.g., reduced hippocampal volume, Yücel et al., 2008b) in long-term cannabis users 
being similar to those observed in patients with schizophrenia, further investigation of neurobiological markers 
of pre-attentive processes may inform mechanisms by which cannabis might result in schizophrenia-like 
conditions in the brain and induce psychosis in vulnerable individuals. 
Sensory gating is the brain’s ability to modulate its sensitivity to incoming stimuli (Braff & Geyer, 1990) 
and includes its ability to inhibit response to irrelevant sensory stimuli and thus ‘gate-out’ repetitive and 
redundant sensory stimulation of the brain (Boutros & Belger, 1999; Boutros et al., 1991; Brenner et al., 2009; 
Freedman et al., 1983; Gjini et al., 2010; Hu et al., 2012). In contrast, ‘gating in’ is conceptualised as the 
brain’s preattentive ability to identify significant stimulus change or novel sensory input (Boutros & Belger, 
1999; Gjini et al., 2010). The P50 component is a positive event-related potential (ERP) marker of sensory 
‘gating-out’
1
 with a vertex maximum elicited approximately 50 milliseconds following an auditory stimulus.  The 
                                                          
1
 In this study, we focus specifically on P50 as a measure of sensory ‘gating-out’ (as defined by Boutros & Belger, 1999; Gjini et al., 2010) 
and do not include a measure of ‘gating-in’ (e.g. mismatch negativity; see Gjini et al., 2010).  While we henceforth refer to ‘P50 sensory 
gating’, we implicitly mean ‘gating-out’ rather than ‘gating-in’. 
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P50 component is typically investigated using an auditory paired-click paradigm in which pairs of brief 
(approximately 1 millisecond) clicks are presented 500 milliseconds apart. In this paradigm, the amplitude of 
the P50 component elicited to the second click is attenuated relative to the first click in healthy individuals. 
The relative reduction in P50 amplitude to the second click within the pair (i.e. the ratio P50 to the second click 
/ P50 to the first click) is the most commonly used marker of sensory gating in this context (Clementz et al., 
1997).  Although the neural generators of the auditory P50 evoked potential have been localised to Heschl’s 
gyrus (Knott et al., 2009; Korzyukov et al., 2007; Weisser et al., 2001), the neurobiological underpinnings 
associated with the phenomenon of sensory gating are less clear (Korzyukov et al., 2007). While it is possible 
that the populations of neurons in the auditory cortex activated to the first click undergo a refractory period 
and therefore cease to be active to the second click, there is increasing evidence to suggest that additional 
inhibitory inputs attenuate the brain’s response to repetitive stimuli and specifically the P50 response to the 
second click (see, Korzyukov et al., 2007). Evidence from animal work suggests these inhibitory inputs may 
arise in the CA3 region of the hippocampus and are involved in sensory gating (Freedman et al., 1996). In 
humans however, intracranial recordings have revealed that hippocampal engagement occurs approximately 
200 milliseconds post-stimulus and therefore, although not directly related to P50 generation (Grunwald et al., 
2003), instead may suppress P50 generators activated by the second click (Korzyukov et al., 2007).  Also 
implicated in sensory gating are generators in the frontal lobe (Korzyukov et al., 2007; Weisser et al., 2001), 
superior temporal gyrus (Thoma et al., 2005), prefrontal cortex (Grunwald et al., 2003), and cingulate and 
parietal lobe regions (Boutros et al., 2013), along with multiple neurotransmitter systems including GABAergic, 
cholinergic, dopaminergic, serotonergic and glutamatergic systems (Adler et al., 1998). Relevant to the 
current study and as noted earlier, THC is thought to disrupt the regulatory action of the endocannabinoid 
system on these neurotransmitter systems (Lopez-Moreno et al., 2008; Mathur and Lovinger, 2012).   
Impaired P50 suppression has been reported extensively in patients with schizophrenia (Bramon et 
al., 2004), and is a candidate endophenotype for the disorder (Braff and Light, 2005) with P50 deficits 
observed at an intermediate level in unaffected family members of patients with schizophrenia (e.g., Clementz 
et al., 1998b) and associated with schizotypy in a non-clinical population (Croft et al., 2001). Meta-analyses 
suggest P50 ratios in patients with schizophrenia are 1.28 to 1.56 standard deviations larger than those of 
healthy controls, although there is large variability in P50 ratios between studies (Bramon et al., 2004; de 
Wilde et al., 2007).  Despite the relatively robust finding of altered sensory gating, the association between 
symptomatology and P50 suppression in patients with schizophrenia is less clear. Croft et al., (2004) argue 
this may be a function of medication status or lifestyle factors such as smoking history. Pharmacological work 
has highlighted the involvement of the α-7 nicotinic receptor in P50 sensory gating (Hajos and Rogers, 2010), 
compatible with improved P50 suppression in cigarette smokers (Crawford et al., 2002) and underlining the 
potential for tobacco use to confound P50 measurement in patient studies given the increased rates of 
smoking in this group (Croft et al., 2004). There is also large variability in P50 measures across studies, 
including the measurement of P50 amplitude (peak to peak vs. baseline to peak), the number of trials 
contributing to an average, time on task and the time between click pairs (inter-pair interval, Dalecki et al., 
2011). 
A small body of research has examined P50 sensory gating in cannabis users. This work has 
reported reduced P50 suppression in chronic cannabis users compared to non-user controls (Edwards et al., 
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2009; Patrick et al., 1999; Patrick and Struve, 2002; Patrick and Struve, 2000; Rentzsch et al., 2007), and 
interestingly in comparison to patients with schizophrenia with and without concurrent cannabis use (Rentzsch 
et al., 2007). Some of these studies found that poor sensory gating in cannabis users is associated with 
prolonged durations of exposure (Rentzsch et al., 2007) and dose (the number of joints smoked in the 
previous six months, Edwards et al., 2009). The association between P50 sensory gating and propensity to 
develop psychotic-like symptoms associated with prolonged exposure to cannabis has not been addressed in 
prior work. Nor have the above studies attempted to control for patterns of tobacco use, which may affect 
these data given the high rates of tobacco use by cannabis users.  The current study attempted to explore 
both of these issues and to clarify the association between prolonged exposure to cannabis and sensory 
gating more precisely. Further, consistent with prior work demonstrating impairments in verbal learning in 
cannabis users and patients with schizophrenia (Solowij and Michie, 2007), we explored a potential 
association between a measure of verbal learning and P50 sensory gating.  Finally, prior research in cannabis 
users focused predominately on a ratio measure of sensory gating (Edwards et al., 2009; Patrick et al., 1999; 
Patrick and Struve, 2002; Patrick and Struve, 2000; Rentzsch et al., 2007), while more recent research also 
investigated the difference metric (P50 amplitude to S1 – P50 amplitude to S2) with mixed results (Edwards et 
al., 2009; Rentzsch et al., 2007). In accordance with this recent work and research which suggests that the 
P50 difference score may be a more reliable index of sensory gating (Smith et al., 1994), the current study 
compared cannabis users with controls on both P50 ratio and difference measures (see also Chang et al., 
2011 for a meta-analysis of S1, S2 and P50 ratio differences in patients with schizophrenia and controls). 
First, we set out to replicate the findings of reduced P50 suppression in chronic cannabis users by comparing 
P50 metrics in regular cannabis users and age- and gender-matched healthy non-user controls. Consistent 
with prior work, we predicted that in comparison to non-user controls, chronic cannabis users would exhibit 
significantly larger P50 ratios, and smaller P50 difference scores, indicative of impaired sensory gating.  
Second, we explored the association between the degree and duration of cannabis exposure, and of 
psychotic-like symptoms, verbal learning and P50 sensory gating.  
 
2.0 Materials and Method 
2.1 Participants 
Twenty-one regular cannabis users and twenty-one non-user controls took part in the study.  
Participants were recruited via an advertisement in a local newspaper and were first screened over the 
telephone to ensure they met inclusion criteria. Regular cannabis use was defined as minimum fortnightly use 
for at least two years. Control participants were required not to have used cannabis more than 20 times in 
their life and not at all in the previous year. Exclusion criteria included regular polysubstance use within the 
previous two years, or use of an illicit substance within the past month (other than cannabis for the cannabis 
group), a current psychiatric diagnosis, and a neurological or medical disease that would interfere with EEG 
testing. Participants were asked to abstain from using cannabis, alcohol or any illicit substance for a minimum 
of 12 hours prior to testing, and self-reported cannabis use and abstinence from other drugs was corroborated 
by urinalysis. Participants also abstained from cigarettes and caffeinated drinks during testing: EEG protocols 
were completed 1.5 hours into the testing schedule. To screen for the presence of a psychiatric condition the 
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Kessler Psychological Distress Scale (K10, Andrews and Slade, 2001) was administered over the phone to all 
participants.  Participants were also asked detailed questions about whether they had ever been diagnosed 
with any psychological/psychiatric disorders as part of a structured interview administered during the testing 
session. One control participant was excluded after they admitted to currently taking an anti-epileptic 
medication. Two participants in the cannabis user group reported that they had used ecstasy on a single 
occasion between 2 and 4 weeks prior to testing. No amphetamine derivatives were detected in their urines 
and therefore data from these participants were included in the analysis. No polysubstance use was reported 
in the non-user control group, and was minimal in the cannabis user group: 2 participants reported regular 
cocaine use over 15 years ago, and two other participants reported a period of regular (approximately 6 
months) amphetamine use over 2 years ago.  The study was approved by the University of Wollongong and 
Illawarra Shoalhaven Local Health District Health and Medical Human Research Ethics Committee.  
2.2 Procedure 
All participants were familiarised with the study procedure before written informed consent was 
obtained. Demographic and detailed substance use information was then obtained through a structured 
interview, and alcohol consumption was assessed using the Alcohol Use Disorder Identification Test (AUDIT, 
Saunders et al., 1993). Full scale IQ was estimated using the vocabulary and matrices subscales of the 
Wechsler Abbreviated Scale of Intelligence (WASI, Wechsler, 1999). All participants were asked to complete 
the Community Assessment of Psychic Experiences (CAPE, Stefanis et al., 2002) and Schizotypal Personality 
Questionnaire (SPQ, Raine, 1991) as measures of psychotic-like symptoms, and cannabis users also 
completed the Cannabis Experiences Questionnaire (CEQ, Barkus et al., 2006) as a measure of symptoms 
experienced while intoxicated, the Marijuana Withdrawal Checklist (MWC, Budney et al., 2004) and the 
Severity of Dependence Scale (SDS, Gossop et al., 2002). The Rey Auditory Verbal Learning Task (RAVLT) 
was also administered to all participants. Handedness was assessed using the Edinburgh Handedness 
Inventory (Oldfield, 1971) and all participants underwent audiometric testing to screen for hearing 
impairments; all were found to have hearing within the normal range (i.e. ≤ 25 dB) at 1000Hz and 1500Hz. 
EEG electrodes were then fitted, and participants first completed an eye-movement calibration task (Croft and 
Barry, 2000) and multi-feature mismatch negativity paradigm (Greenwood et al., in revision; Todd et al., 2008) 
before completing the P50 paired-click paradigm. All participants were reimbursed AUD$50 for their 
participation.  
2.3 Experimental paradigm 
The P50 task comprised one 10-minute block of 100 pairs of click stimuli. To control attention, 
participants were instructed to silently count each of the pairs of clicks and respond with a button press after 
every 25
th
 click pair. Prior research suggests there are no differences between ‘active’ paradigms which 
control attention by counting or button pressing, and passive paired click paradigms on P50 metrics (Jerger et 
al., 1992; Kho et al., 2003; White & Yee, 1997). Participants were asked to minimise movement and to keep 
their eyes open, resting their gaze on the computer monitor in front of them. The stimuli were auditory clicks of 
1 ms duration and presented binaurally using headphones (Sennheiser HD215) at 90 dB SPL.  The first and 
second clicks within a pair were separated by a fixed inter-stimulus interval of 500 ms.  The inter-pair interval 
(IPI) was the duration between the second click within a click pair and the first click of the next pair. There 
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were two different IPI conditions, a long IPI condition in which click pairs were presented with an average of 9 
seconds apart (in order to give the appearance of randomness, 3 different IPIs were chosen for each 
condition, the mean of which was the target IPI:  e.g. 8930, 8990 or 9080ms) and a short IPI condition in 
which click pairs were presented an average of 3 seconds apart. The current study will focus on data from the 
9 second IPI condition as this condition is most comparable to paired-click paradigms employed in previous 
research (e.g., Edwards et al., 2009; Patrick et al., 1999; Patrick and Struve, 2002; Patrick and Struve, 2000; 
Rentzsch et al., 2007). Data for the 3 second IPI condition were collected as part of another study and will not 
be discussed further here. Fifty pairs of each of the short and long IPI conditions were presented in a random 
fashion.  
2.4 Electrophysiological data acquisition 
Electroencephalographic (EEG) data were recorded continuously from 19 Ag/AgCl electrodes 
positioned on an Electrocap according to the international 10-20 system (FP1, FP2, F3, Fz, F4, F7, F8, C3, 
Cz, C4, P3, Pz, P4, T3, T4, T5, T6, O1 and O2), and two electrodes positioned over the left and right mastoid. 
EEG data were grounded to an electrode placed midway between FPz and Fz, and referenced online to an 
electrode positioned on the tip of the nose. Four monopolar electrodes were placed above and below the left 
eye and 1 cm from outer canthi of the left and right eye and used to calculate vertical, horizontal and radial 
electrooculogram (EOG) data required for the EOG correction procedure of Croft and Barry (2000). Data were 
sampled at 500 Hz, with a bandpass filter of 0.1 to 100 Hz.  All electrode impedances were below 10 kΩ at the 
start of recording. 
2.5 Electrophysiological data analysis 
EEG data were analysed offline using Neuroscan software (Scan 4.4).  Data were re-referenced 
offline to the average of the mastoids and corrected for ocular artifacts according to Croft and Barry (2000).  
Data were bandpass filtered from 10 to 45 Hz (down 12 dB/octave roll off), epoched from 100 ms pre-stimulus 
to 300 ms post-stimulus, and baseline corrected using the 100 ms pre-stimulus interval.  Epochs were 
rejected if signals at any EEG channel exceeded ± 50 µV. EEG epochs were then averaged to the first (S1) 
and second (S2) click.  
P50 peaks were identified as the largest positive peak ± 15 ms around the peak of the average P50 
peak latency in the grand mean (i.e. 62 ms ± 15 ms) following the Na peak (i.e. 48 ± 15 ms) and were 
required to have a frontocentral topography (Rentzsch et al., 2007). No minimum peak amplitude was 
required for a peak to be classified as such. An automatic peak detection algorithm was applied first and the 
data were then verified visually by an experienced researcher, although not blind to group status. If no peak 
was present within the specified latency range and/or did not have a frontocentral topography, the P50 
amplitude was scored as ‘0’ (see also Dalecki et al., 2011). P50 data were measured at Cz only, in 
accordance with Clementz et al., (1998a), relative to the peak of the preceding peak (Na).  The following P50 
measures were computed: P50 peak to peak amplitude to the first (S1) and second (S2) click; P50 ratio, 
defined as the ratio of P50 peak amplitudes (i.e. S2/S1, where smaller P50 ratios are indicative of better 
sensory gating); and P50 difference, defined as the difference between P50 peak amplitude to the first and 
second click (i.e. S1- S2, where larger difference scores are indicative of better sensory gating).  
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2.6 Statistical analysis 
The groups were compared on demographic variables and measures of psychotic-like symptoms 
using independent samples t-tests (or Mann-Whitney U tests where data were not normally distributed). P50 
measures were not consistently normally distributed in the chronic cannabis user group, so all data were 
transformed using a square root transformation to approximate normality. Univariate ANOVAs were then used 
to examine the effect of Group (cannabis, control) on each transformed P50 variable (P50 amplitude to the 
first (S1) and second (S2) click stimuli, P50 ratio and P50 difference). Pearson’s correlations were used to 
examine the association between transformed P50 measures and cannabis use measures (also transformed 
using a natural log transformation, and including duration of regular (weekly and daily) cannabis use, 
frequency and quantity of use, age at which participants first tried cannabis, age of onset of regular use, 
number of hours since participants last smoked cannabis, and urinary cannabinoid metabolite levels (THC-
COOH, creatinine normalised)). Given the previously reported association between P50 gating, nicotine 
exposure and α-7 nicotinic receptor activity, we re-ran the aforementioned correlations using Pearson’s partial 
correlations controlling for tobacco use defined as the number of cigarettes smoked per day. To further 
examine the effect of prolonged exposure to cannabis on P50, the cannabis group was divided into short- and 
long-term users using a median split procedure. Univariate ANOVAs compared P50 amplitude to S1 and S2, 
P50 ratio and P50 difference scores in short- and long-term users with non-user controls and with each other. 
Finally, a natural log transformation was applied to the following variables: CAPE total frequency score, CAPE 
total distress score, SPQ  total score, CEQ Euphoric experiences score, CEQ Paranoid Dsyphoric score, CEQ 
Amotivational score, CEQ After effects score and CEQ psychotic like experiences score. With the exception of 
MWC score, RAVLT total score and SPQ total score, all other variables were successfully transformed. 
Pearson’s correlations were used to explore the association between P50 ratio and difference score and 
CAPE total frequency and distress scores as well as each CEQ subscale. Spearman’s correlations were used 
to examine the association between the untransformed MWC score, RAVLT total score and SPQ total score 
and P50 measures. P50 data (transformed) were examined for outliers (±1.5 times the inter-quartile range) 
and analyses were repeated with and without identified outliers excluded. Where the pattern of effects 
remained unchanged the data were retained in their original form and the analyses with all cases included are 
reported. Where the pattern of results changed following the exclusion of outliers, the data are reported with 
and without outliers included.  
 
3.0 Results 
3.1 Demographic, substance use and psychotic-like symptoms 
Demographic, substance use and psychotic-like symptom measures for cannabis users and controls 
are provided in Table 1. Cannabis users did not differ significantly from controls in terms of age or gender. All 
participants were right-handed. Cannabis users had used cannabis regularly for a median 9.4 years (range 
2.6 to 36.0 years), at a rate of approximately 4 joints per day on a median of 27 days per month (range 15 to 
30 days/month). Cannabis users had significantly fewer years of education, lower IQ scores and recalled 
significantly fewer words than controls on the RAVLT. Cannabis users consumed a greater quantity of alcohol 
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and tended to drink more frequently than controls. However none of these variables were found to correlate 
with P50 (S1 or S2 amplitudes, P50 ratio or P50 difference score; all p values > .10 for the control group, and 
p > .29 for the cannabis group) and were therefore not appropriate for inclusion as covariates in subsequent 
analyses. Cannabis users also smoked more cigarettes per day than controls, and although P50 metrics were 
not associated with cigarettes per day in the cannabis group (p values > .80), given the aforementioned 
association with P50 gating in the literature and an association between duration of cannabis use and 
cigarettes smoked per day (r(21) = .59, p = .02) in the current dataset, we controlled for the possible effects of 
tobacco use on P50 when testing for associations with cannabis use, using partial correlations. Finally, 
although cannabis users tended to have higher CAPE total frequency scores compared to controls, the 
groups did not differ in terms of total CAPE distress or SPQ scores.  
3.2 Sensory gating in cannabis users and non-user controls 
Grand mean ERP waveforms to the first (S1) and second (S2) click at Cz are presented for cannabis 
users and controls in Figure 1 and mean (SD) P50 amplitude to S1 and S2, P50 ratio and difference score are 
presented in Table 2. Cannabis users were not found to differ from controls in terms of P50 amplitude to S1 
(F(1,39) = 0.99, p = .33), P50 amplitude to S2 (F(1,39) = 0.45, p = .51) or P50 difference score (F(1,39) = 
2.57, p = .12). A main effect of group reached trend level for P50 ratio (F(1,39) = 3.44, p = .07) indicating 
larger P50 ratios in cannabis users relative to controls. However, two outliers were identified in the control 
group and when the analysis was repeated without these cases included, the effect of group was non-
significant (F(1,37) = 1.15, p = .22). P50 ratio and difference scores were found to be significantly associated 
with the overall duration of regular use (P50 ratio: r(21) = .44, p = .05, P50 difference: r(18) = -.49, p = .04; 
see Figure 2) and P50 ratio tended to be associated with the duration of daily cannabis use (r(18) = .46, p = 
.054) indicating larger P50 ratio and smaller P50 difference scores (worse sensory gating) with prolonged 
exposure to cannabis. After controlling for cigarette use in partial correlations, the association between P50 
ratio and duration of cannabis use was reduced to trend level (r(13) = .48, p = .07), while the association with 
P50 difference score remained significant (r(13) = -.69, p = .01). Further, the association between P50 ratio 
and duration of daily use was no longer significant after controlling for cigarette use (r(11) = .46, p = .12).  No 
association was identified for P50 ratio or difference score and any other measure of cannabis use (all p 
values > .10; including after controlling for cigarette use).  Finally, no associations between P50 ratio nor P50 
difference score and time since last use (p values > .80), urinary cannabinoid metabolite levels (p values > 
.10) or score on the MWC  (p values > .10) were identified.  
3.3 Sensory gating in long- versus short-term cannabis users 
Grand mean ERP waveforms to the first (S1) and second (S2) click at Cz are presented for short- and 
long-term cannabis users and controls in Figure 3 and mean (SD) P50 amplitude to S1 and S2, P50 ratio and 
difference score are presented in Table 2. In terms of group characteristics, long-term cannabis users had 
used cannabis regularly for a median of 23.2 years, and were currently using approximately 2 joints per day 
for a median of 26 days per month.  Short-term users had used cannabis regularly for a median duration of 
6.1 years and used approximately 4 joints per day, on a median 29 days per month. Long-term users were 
older than short-term users, had used cannabis regularly for longer and reported fewer withdrawal symptoms, 
but did not differ in any other cannabis use parameters. Compared to controls, short-term users had 
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significantly higher CAPE frequency scores and recalled significantly fewer words on the RAVLT. Age was not 
found to be associated with any P50 measure for controls (p values > .10), short-term (p values > .10) or long-
term cannabis use groups (p values > .19). Since age and duration of cannabis use were highly correlated 
(rho = 0.734, p = .002), and age did not correlate significantly with any P50 measure for any group, age was 
not considered appropriate for inclusion as a covariate. 
Short-term cannabis users did not differ from controls in terms of any P50 measure (P50 S1: F(1,28) 
= 0.06, p = .80; P50 S2: F(1,28) = .02, p = .90; P50 ratio: F(1,28) = 0.37, p = .55); P50 difference 
score:F(1,28) = 0.21, p = .65). For the comparison of long-term users and controls, no effect of group was 
observed for P50 amplitude to S1 (F(1,29) = 1.45, p = .24) or S2 (F(1,29) = 0.75, p = .39), however a 
significant effect of group was observed for P50 ratio (F(1,29) = 5.64, p = .02) and P50 difference score 
(F(1,29) = 4.35, p = .05), such that P50 ratios were increased and P50 difference scores decreased in long-
term cannabis users. 
Finally, for the comparison of long- and short-term users, no effect of group was identified for P50 to 
S1 or S2, P50 ratio or difference score (P50 S1: F(1,19) = 1.50, p = .24; P50 S2: F(1,19) = 0.65, p = .43; P50 
ratio: F(1,19) = 2.53, p = .13; P50 difference: F(1,19) = 2.21, p = .15). However for P50 amplitude to S1, one 
outlier in the long-term group was identified, and for P50 ratio and difference score, 1 outlier was identified in 
the short-term group. When the analysis was repeated with these outliers excluded, long-term users were 
found to have significantly reduced P50 S1 amplitude, significantly larger P50 ratios and significantly smaller 
difference scores than short-term users (P50 S1: F(1,18) = 5.64, p = .03; P50 ratio: F(1,18)=4.47, p = .05; P50 
difference: F(1,18) = 5.06, p = .04). Furthermore, no association between P50 ratio or difference score, and 
recency of cannabis use (time since last used and urinary cannabinoid metabolite levels) or withdrawal 
measures (MWC score), was observed in either the long- or short-term user groups (all p values > .08). 
3.4 Associations between P50 metrics, verbal learning and psychotic-like symptoms in 
cannabis users 
No association between our measure of verbal learning or any measure of psychotic-like symptoms 
and P50 ratio or difference score was observed in the total sample of cannabis users, or in the short- or long-
term user groups (all p values > .10).  
 
4.0 Discussion 
In this study we report an association between prolonged durations of exposure to cannabis and 
larger impairment in sensory gating as indexed by P50 ratio and difference scores. Consistent with prior work, 
long-term cannabis users were found to exhibit larger P50 ratios relative to controls, and we also found 
evidence for reduced P50 difference scores. Previous studies of cannabis users that included P50 difference 
scores reported mixed results: Edwards et al., (2009) found that only P50 ratio but not P50 difference scores 
differentiated cannabis users from controls, while Rentzsch et al., (2007) reported significantly larger P50 
ratios and P50 difference scores in cannabis users. The latter study, however, focused all subsequent 
analyses on P50 ratio only and did not explore P50 difference scores further. Although the group difference 
for P50 ratio in our overall sample of cannabis users and controls reached trend level only, we observed an 
Chronic effects of cannabis on sensory gating                      11 
association between duration of cannabis use and P50 metrics suggesting protracted exposure to cannabis 
was associated with impaired sensory gating even after controlling for tobacco use. Rentzsch and colleagues 
(2007) also reported an association between P50 gating and daily cannabis consumption, while Edwards et 
al. (2009) found an association between gating and the quantity of cannabis used in the previous six months. 
Neither study accounted for the possible effect of cigarette smoking on these measures. The current study 
represents the first attempt to account for tobacco use when examining P50 metrics in cannabis users.  
To explore the nature of the effect of duration of cannabis use on P50 further, we used a median split 
to divide the sample of users into long- and short-term user groups, finding significantly larger P50 ratios and 
reduced P50 difference scores (indicative of a gating deficit) in long-term users compared to non-user controls 
and short-term users. Interestingly however, the short-term user group had a history of exposure to cannabis 
that was more similar to the duration of use of the samples of cannabis users in the studies of Edwards et al. 
(2009) and Rentzsch et al. (2007), with significantly fewer years of cannabis use than the median 23 years of 
our long-term users. Nevertheless, the current pattern of findings highlights the importance of the duration of 
exposure on sensory gating, and suggests the P50 difference score may be particularly sensitive to deficits in 
long-term cannabis users. P50 difference scores are arguably a more psychometrically reliable method than 
P50 ratio (Smith et al., 1994), however it is also possible that P50 ratio and difference scores may reflect 
slightly different neurobiological processes (Smith et al., 1994) and this may in part account for the difference 
in the pattern of results we report here as a function of cannabis use and prior research (e.g., Edwards et al., 
2009). Long-term users were also observed to have significantly smaller P50 amplitude to the first click, a 
finding consistent with the patient literature (e.g. Clementz and Blumenfeld, 2001; Smith et al., 2010) and 
suggests long-term exposure to cannabis may adversely affect encoding as well as well as gating (Smith et 
al., 2010).  
Consistent with prior work, cannabis users exhibited impaired verbal learning memory compared to 
controls (Solowij and Michie, 2007), although no association with P50 measures was observed. We also set 
out to explore a possible association between the presence of psychotic-like symptoms in cannabis users and 
P50 sensory gating deficits as a potential marker of vulnerability to psychosis. Although prior work has found 
an association between P50 ratio and schizotypy in non-clinical populations (Croft et al., 2004; Croft et al., 
2001), the current study did not observe any association between P50 metrics and psychotic-like symptoms in 
long-or short-term cannabis users, including a retrospective measure of psychotic-like symptoms during 
intoxication. This lack of association bears some similarity with the inconsistent relationship between 
symptomatology and P50 deficits reported in patients with schizophrenia (Potter et al., 2006). Further, it 
should be noted that only the short-term users in our sample differed significantly from controls in terms of one 
measure of psychotic-like symptomatology (CAPE frequency scores), and this suggests that perhaps the 
current sample of cannabis users were not particularly psychosis-prone (consistent with no clear differences 
between controls and cannabis users on our two measures of psychotic-like experiences). Our study 
exclusion criteria were strict with regard to psychiatric history, and it is plausible that our sample of cannabis 
users were less susceptible to developing psychosis, particularly given that despite their prolonged histories of 
exposure to cannabis, none had developed psychosis. It is also interesting however, that short-term users 
reported a greater number of paranoid dysphoric and psychotic-like experiences during intoxication compared 
to long-term users. One possibility is that given their younger age, short-term users may have been exposed 
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to more potent (high THC content) forms of cannabis during a neurodevelopmentally critical period associated 
with these increased psychotic-like experiences, although we did not observe a significant effect on P50 
gating. This group difference should also be considered alongside demographic differences between short- 
and long-term groups including a greater proportion of males, younger age and lower IQ scores in the short-
term group which may also have influenced sensory gating effects and associations between P50 metrics and 
psychotic-like experiences.  Nevertheless, in light of increasing evidence of an association between cannabis 
and psychosis, and the fact that P50 deficits are extensively reported in patients with schizophrenia, and 
those at risk of developing the disorder (Bramon et al., 2004), our findings provide some support for the notion 
that chronic cannabis use may result in an underlying pathology similar to schizophrenia (Solowij and Michie, 
2007).  
The mechanisms by which exogenous cannabinoids such as THC might affect P50 gating are largely 
unknown, however consistent with rat models of sensory gating (Boutros et al., 1997; Boutros and Kwan, 
1998; Dissanayake et al., 2013), as well as intracranial recordings in humans which have implicated 
hippocampal involvement (e.g., Grunwald et al., 2003), disrupted sensory gating in cannabis users might be 
due to the partial agonist effects of THC at CB1 receptors in the hippocampus in terms of reducing GABAergic 
inhibition of excitatory glutamatergic neurons (Dissanayake et al., 2013). This could lead to deficits in 
inhibitory processing, including reduced inhibitory inputs to P50 generators in auditory and frontal cortices.  
Consistent with this notion, when CB1 agonists were administered to rats, sensory gating was disrupted as 
measured by local field potentials in the CA3 region of the hippocampus (Dissanayake et al., 2008; Hajos et 
al., 2008) as well as the medial prefrontal cortex (Dissanayake et al., 2008). Further work, however, is 
required to elucidate the interaction between cannabis, the endogenous cannabinoid and other 
neurotransmitter systems such as prefrontal dopamine circuits which have also been implicated in sensory 
gating (for a review see, Gallinat et al., 2012). A related methodological issue is the use of an active paradigm 
in order to control attention and the possibility of differential effects of attention as a function of group status 
on sensory gating. To date, research examining the effects of cannabis on P50 has used both active attention 
paradigms (e.g. Edwards et al., 2009) and passive tasks (e.g. Patrick et al., 1999; Rentzsch et al., 2007). Gjini 
et al. (2011) found attention to S2 increased the S1 response in both healthy controls and patients with 
schizophrenia, while only S2 amplitudes increased as a function of attention in healthy participants. This 
resulted in improved sensory gating ratios in patients, and a reduced group difference (Gjini et al., 2011).  
Future studies might consider using both passive and active paired click paradigms in order to ascertain 
whether attention might have a differential effect on sensory gating in cannabis users.  
There are a number of limitations in the current study that may be addressed in future work. First, 
future research could extend these findings to a larger sample of cannabis users. Second, further 
consideration of study inclusion/exclusion criteria regarding personal and familial psychiatric history to include 
potentially more psychosis-prone individuals might address the efficacy of P50 deficits in cannabis users as a 
possible marker of vulnerability to psychosis. For example, longitudinal work investigating P50 deficits and the 
development of psychotic symptoms would serve to clarify the role of chronic cannabis exposure and 
vulnerability to psychosis, and genetic moderation of effects might be examined. Third, it is possible that the 
P50 deficits we observed in long-term users may have pre-existed cannabis use, although the association 
with duration of use and impaired sensory gating ratios suggests this is unlikely. Nevertheless, longitudinal 
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work would facilitate our understanding of premorbid functioning in cannabis users and help clarify the role of 
prolonged exposure to cannabis on these measures. Fourth, although the current findings are most likely the 
result of chronic cannabis use, there are alternative explanations including possible residual effects of THC 
associated with recent use (Pope et al., 2001) or effects associated with withdrawal (Budney et al., 2004). 
However these explanations are unlikely as we found no association between P50 measures and either 
recency of cannabis use (time since last use or urinary cannabinoid metabolite levels) or withdrawal 
measures. Participants in the current study were asked to abstain from using cannabis (alcohol or any other 
illicit substance) for at least 12 hours prior to the experiment (median time since last use was 15 hours), so 
they were not acutely intoxicated and withdrawal effects were minimal. Future work however could examine 
the acute effects of cannabis on P50 metrics in regular and non-naive non-users to address these issues. 
Finally, while we found age to not be correlated with P50 measures in any group in our sample (although see 
Patterson et al. (2008) for a review of age effects on P50 gating in patients with schizophrenia), it is difficult to 
disentangle the effects of age and duration of use (long-term cannabis users were older than short-term 
users) on sensory gating. Future work should attempt to better match long- and short-term cannabis use 
groups on demographic variables such as age to more fully understand and interpret these effects. Future 
work might also examine the contribution of altered neural oscillations to sensory gating deficits in chronic 
cannabis users (see also Edwards et al., 2009) as well as applying wider filter settings to examine the 
potential role of lower frequency oscillations in P50 sensory gating (see Jansen et al., 2004).  
In summary the findings from the current study suggest that regular, long-term exposure to cannabis 
may be associated with impairments in auditory sensory gating as indexed by P50 metrics.  P50 deficits are 
also extensively reported in patients with schizophrenia and arguably represent a candidate endophenotype 
for the disorder. In combination, mounting evidence of cognitive, electrophysiological, structural and functional 
brain abnormalities observed in chronic cannabis users and patients with schizophrenia, along with the 
current data suggest chronic cannabis use may result in schizophrenia-like conditions in the brain with 
common underlying pathology (Solowij and Michie, 2007). Impairments in sensory gating processes as a 
result of chronic exposure to cannabis may be related to disruption of the regulatory role of the 
endocannabinoid system on synaptic neurotransmission, and particularly the disruption of CB1 receptor 
activity in hippocampal and anterior cortical regions. 
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Table 1. Demographic data, substance use measures and symptoms in cannabis user and healthy nonuser control groups. Median (range) are displayed. 
 Control (C) 
n = 20 
Cannabis (ALL) 
n = 21 
Short-term (S-T) 
n = 10 
Long-term (L-T) 
n = 11 
All v C S-T v C L-T v C S-T v L-T 
 p p p p 
Age (years) 24.7 (18.1-52.6) 26.4 (18.5-52.0) 20.5 (18.5-26.4) 39.61 (21.4-52.0) .696 .214 .072 .000 
Gender (M/F) 8/12 14/7 8/2 6/5 .121 .058 .477 .361 
IQ
a
 112.5 (89-125) 104 (86-135) 94 (86-116) 109 (94-135) .040 .000 .910 .005 
Education (years)
a
 14.3 (11.5-18.0) 12.0 (10.0-17.0) 12.1 (11.0-14.0) 12.0 (10.0-17.0) .001 .000 .020 .666 
RAVLT (Total 1 to 5) 56.5 (29.0-71.0) 45.0 (28.0-62.0) 42.5 (28.0-52.0) 49.0 (29.0-62.0) .002 .000 .095 .223 
Cigarettes per day 0 (0-11) 4 (0-20) 2.5 (0.0-12.5) 7.0 (0.0-20.0) .000 .017 .000 .099 
Alcohol frequency (days/month) 2.1 (0.0-4.0) 30.0 (0.0-30.0) 2.5 (0.0-10.0) 3.0 (0.0-30.0) .099 .397 .079 .349 
Alcohol quantity (drinks /month) 6.4 (0.0-70.0) 20.0 (0.0-180.0) 14.9 (0.0-96.0) 21.0 (0.0-180.0) .049 .131 .095 .863 
Psychotic-like symptoms         
CAPE Frequency total 57 (45-89) 64 (50-90) 65 (52-92) 64 (42-84) .099 .040 .471 .314 
CAPE Distress total 17 (4-50) 32 (13-79) 36 (13-79) 27 (0-53) .196 .069 .735 .223 
SPQ total 12 (0-39) 27 (0-42) 33 (1-42) 21 (0-34) .220 .157 .576 .128 
CEQ Euphoric experiences - 49 (29-72) 44 (35-56) 37 (29-72) - - - .105 
CEQ Paranoid Dsyphoric - 44 (25-76) 48 (33-76) 33 (25-56) - - - .024 
CEQ After effects - 22 (0-50) 23 (0-50) 19 (11-28) - - - .274 
CEQ Amotivational - 14 (0-34) 14 (0-34) 15 (7-21) - - - .621 
CEQ Psychosis-like experiences - 6 (0-16) 10 (0-16) 5 (4-9) - - - .025 
Cannabis Use         
Hours since last use - 15 (13-168) 14 (13-48) 18 (13-168) - - - .083 
Frequency (days/month) - 27 (15-30) 29 (20-30) 26 (15-30) - - - .433 
Quantity (cones/month) - 338 (34-3150) 372 (138-3150) 195 (34-1080) - - - .523 
Age of first use (years) - 14.5 (10-19) 14.8 (10-16) 13.5 (11-19) - - - .859 
Age started regular use (years) - 16 (10-21) 15.5 (10-19) 16 (13.5-21.0) - - - .391 
Duration of regular use (years) - 9.4 (2.6-36.0) 6.1 (2.6-8.4) 23.2 (9.4-36.0) - - - .000 
Duration of daily use (months) - 60 (0.25-204.0) 30 (0.25-88.3) 72.0 (12.0-204.0) - - - .062 
MWC (withdrawal) score - 6.50 (1-33) 12.5 (2-33) 4.5 (1-11) - - - .008 
Urinary cannabinoid metabolite 
(THC- COOH) (ng/ml) 
- 745 (108-9351) 828 (239-3658) 393 (108-9351) - - - .130 
Notes: 
a.
Parametric tests performed (independent samples t-test). Significant p < .05 are noted by italics
Table(s)
 
Table 2.Mean (SD) P50 metrics for healthy nonuser controls, cannabis users (all), short-term and long-term user groups.  
 
       
 
P50 metric Control (n = 20) Cannabis (All; n = 21) 
Short-term users 
(n=10) 
Long-term users (n=11) 
 
 
P50 S1 amplitude (μV) 4.55 (3.03) 3.51 (1.81) 3.87 (1.22) 3.18 (2.22) 
 
 
P50 S2 amplitude (μV) 1.39 (1.10) 1.50 (1.04) 1.25 (0.70) 1.71 (1.28) 
 
 
P50 ratio (S2/S1) 0.32 (0.24) 0.50 (0.40) 0.37 (0.29) 0.63 (0.45) 
 
 
P50 difference score (S1-S2)  3.17 (2.41) 2.02 (1.73) 2.62 (1.43) 1.47 (1.85) 
 
        
 
Figure captions 
Figure 1: ERP waveforms to the first (S1; left) and second (S2; right) click at Cz. Cannabis users are shown in grey and control participants in black. 
Amplitude is shown in μV on the y-axis and time in milliseconds along the x-axis. 
Figure 2: Scatter plots showing association between P50 metrics (after square root transformation) and duration of regular cannabis use in years (after 
natural log transformation) in cannabis users. P50 ratio (transformed) shown on left and P50 difference score (transformed) shown on right. 
Figure 3: ERP waveforms to the first (S1; left) and second (S2; right) click at Cz. Short- and long-term cannabis users are shown in the solid grey thin and 
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